Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigulixostat PK/PD in Renal Impairment
NCT04066712Phase 1Completed
- Sponsor
- LG Chem
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tigulixostat in gout and hyperuricemia (4 arms), sponsored by LG Chem. Primary endpoints: Area under the concentration-time curve from time 0 to the last quantifiable concentration, Area under the concentration-time curve from time 0 to 24 hours post dose and 4 more. Started Nov 2019; status: completed.
02
Drugs
tigulixostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04066712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066712.